Trending Now
Synaptogenix Inc (NASDAQ: SNPX) Announces a Peer-reviewed Paper on Bryostatin
Synaptogenix Inc (NASDAQ: SNPX) announced a peer-reviewed paper published in the Frontiers Aging Neuroscience. The paper came from a collaboration between the company’s Chief...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
S&P 500 had its worst day in more than a month...
The Dow Jones Industrial Average tumbled more than 600 points on Wednesday as investors took profits on some of the strong January...
MAKE IT MODERN
LATEST REVIEWS
Enveric Biosciences Inc (NASDAQ:ENVB) Enters Deal To Acquire Diverse Biotech’s Exclusive...
Enveric Biosciences has received an exclusive license from Diverse Biotech. The license gives the company a nod to undertake the development of new drugs...
MAKE IT MODERN
PERFORMANCE TRAINING
Kura Oncology Inc. (NASDAQ:KURA) Reports Q3 2020 Results And Announces Presentation of KO-539 Results...
Kura Oncology Inc. (NASDAQ:KURA) has announced its Q3 2020 financial results and also provided a corporate update.
The company reported a net loss of $23.8...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Clinches $450 Million Deal From The US Government To Produce...
The Trump administration awarded a $450 million contract under ‘Operation Warp Speed’ to Regeneron Pharmaceuticals Inc (NASDAQ:REGN)(RPC) to develop and quickly distribute the antibody...
Neurotrope Inc. (NASDAQ:NTRP) Announce Commencement Of New Long Term Study Bryostatin-1 in Treatment of...
Neurotrope Inc. (NASDAQ:NTRP) has announced the launch of a new second phase study of Bryostatin-1 for the treatment of Alzheimer's disease patients.
Neurotrope receives $2.7...
Regulus Therapeutics Inc. (NASDAQ: RGLS) strategically Prioritizing RGLS8429 for Autosomal Dominate Polycystic Kidney Disease...
Regulus Therapeutics Inc. (NASDAQ: RGLS) has announced prioritizing of its next-gen RGLS8429 drug candidate for Autosomal Dominant Polycystic Kidney Disease treatment.
Regulus finalized dosing in...
Dynavax Technologies Corporation (NASDAQ:DVAX) Completes Enrolment IN Study Evaluating Hepatitis B Vaccine, HEPLISAV-B
Dynavax Technologies Corporation (NASDAQ:DVAX) has announced the completion of registration of 119 patients in its clinical study evaluating its Hepatitis B vaccine HEPLISAV-B in...
MAKE IT MODERN
